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INTRODUCTION
Atopy is characterized by enhanced immunoglobulin E
(IgE) response to common environmental antigens and leads
to clinical disorders such as asthma, eczema and rhinitis (1).
Allergic inflammation and IgE synthesis are known to be a
T helper (Th) 2 phenomenon promoted by a distinctive aller-
gen-specific Th2 cell subset (2). 
Th cells can be divided into two subpopulations, Th1 and
Th2, based on the cytokines they produce. Th2 cells produce
interleukin (IL)-4, IL-5 and IL-13, which cause eosinophilia
and promote immunoglobulin class switching to IgE (3).
Th1 cells produce interferon (IFN)- , which inhibit Th cells
to differentiate to Th2 cells and down-regulates the produc-
tion of IgE. 
IL-12 is the single most powerful factor inducing the syn-
thesis of IFN- and acts by binding to its specific receptor.
The receptor of IL-12 (IL-12R) is composed of two subunits,
1 and  2, that assemble to form a high affinity IL-12 recep-
tor complex (4). While the  1 subunit is relatively constantly
expressed, the  2 subunit expression is restricted to Th1 cells
and highly regulated by several cytokines. 
Several investigators have shown that peripheral blood mo-
nonuclear cells (PBMCs) from atopic patients produced less
IFN- than those of healthy individuals when they were sti-
mulated with IL-12 (5-9). The underlying mechanisms of
the low responsiveness to IL-12 in atopic patients have not
been known. In one study, reduced expression of IL-12R 2
mRNA was found to have relation with low production of
IFN- in atopic patients (13). They explained that the dec-
reased capacity of up-regulation of IL-12R 2 might decrease
the responsiveness of Th1 cells to IL-12. In another study,
RNA editing, especially, nucleotide 2451 C-to-U conversion
of IL-12R 2, was reported in atopic patients (1). They sug-
gested that above RNA editing might give rise to a confor-
mational change in IL-12R 2 and cause impairment of Th1
cells to respond to IL-12. 
The aim of this study was to investigate mRNA expression
of IL-12R 2 as well as the RNA editing, nucleotide 2451
C-to-U conversion, of IL-12R 2 as a possible cause of low
responsiveness to IL-12 in atopic patients. In additional eval-
uation, the correlation of the IL-12R 2 mRNA expression
with serum total IgE concentration and blood eosinophil
count were evaluated in atopic patients. 
MATERIALS AND METHODS
Subjects
Eighty atopic patients (52 male, 28 female, 34.2±18.9 yr)
with major allergic diseases such as bronchial asthma (10 male,
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mRNA Expression and RNA Editing (2451 C-to-U) of IL-12 Receptor
2 in Adult Atopic Patients
Interleukin (IL)-12 activates T helper (Th) 1 cells to produce interferon (IFN)- which
inhibits atopic inflammation. IL-12 acts through interaction with its receptor, espe-
cially  2 subunit. In several studies, the low production of IFN- in peripheral mononu-
clear cells of atopic patients on response to IL-12 stimulation has been reported.
Therefore we investigated the IL-12 receptor  2 (IL-12R 2) mRNA expression and
RNA editing, nucleotide 2451 C-to-U conversion, to find the cause of low respon-
siveness to IL-12 in atopy. Quantitative real time PCR for mRNA expression and
sequence analysis for RNA editing were performed in 80 atopic patients and 54
healthy controls. The expression of IL-12R 2 mRNA was significantly lower in atopic
patients than healthy controls (p<0.05). In sequence analysis, RNA editing on nucle-
otide 2451 was not found from either atopic patients or healthy controls. In additional
evaluation, there was no relationship between expression of IL-12R 2 mRNA and
serum total IgE or blood eosinophil count. Reduced IL-12R 2 mRNA expression in
atopic patients indicate the reduced capacity to respond to IL-12 which induce IFN-
production and this may contribute to Th2-skewed immune response in atopy. 
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4 female, 30.7±22.1 yr), atopic dermatitis (26 male, 15 fe-
male, 36.5±18.5 yr) or allergic rhinitis (17 male, 8 female,
31.6±18.1 yr) were studied. The diagnosis of allergic dis-
eases was established by specific allergic symptoms, positive
results of allergen specific IgE test and/or increased serum total
IgE concentration. Fifty four healthy controls (23 male, 31
female, 47.1±14.3 yr) who had no history of atopic disease
and had normal serum total IgE concentration were studied.
Methods
Venous blood was drawn from atopic patients and healthy
controls. PBMCs were isolated by gradient centrifugation
method using Ficoll-PaqueTMplus (Amersham Biosciences,
Uppsala, Sweden) and were suspended in the RPMI 1640
(Invitrogen, Grand Island, NY, U.S.A.) culture medium in
1×106 density. Then the cells were cultured in the presence
of 10  g/mL PHA for 24 hr at 37℃ in a humidified atmo-
sphere containing 5% CO2 (Forma CO2 incubator model
3039, Formal Scientific Inc, Ohio, U.S.A.). 
Total cellular RNA was extracted from cultured PBMCs
using High Pure RNA isolation kit (Roche, Penzberg, Ger-
many) and 5  g of RNA was converted to complementary
DNA (cDNA) by reverse transcription (RT) PCR in a total
reaction mixture volume of 20  L. The real time PCR reac-
tions for quantification of IL-12R 2 cDNA and GAPDH
(Glyceraldehyde-3-phosphate dehydrogenase) were performed,
respectively. GAPDH was analyzed as an internal control. The
master PCR reaction mixure was contained 2  L of Light-
Cycler
� FastStart DNA master SYBR green I (Roche Molec-
ular Biochemicals, Mannheim, Germany), 2.5  L of MgCl2
in final concentration of 4 mM, each 10 pM of sense and
antisense primers, 2  L of cDNA and distilled water in final
volume of 20  L. The LightCycler
� FastStart DNA master
SYBR green I was composed of Taq DNA polymerase, SYBR
green I dye, 10 mM MgCl2 and dNTPs (dATP, dCTP, dGTP,
dUTP) in the reaction buffer. The PCR thermal conditions
were as follows: 10 min at 95℃ and 40 cycles of 10 sec at
95℃, 5 sec at 57℃ and 4 sec at 72℃ for IL-12R 2 and 10
min at 95℃ and 40 cycles of 10 sec at 95℃, 5 sec at 55℃
and 15 sec at 72℃ for GAPDH. The primer sequences were
summarized in Table 1. The quantitative real time PCR was
performed using LightCycler
� system (Roche Molecular Bio-
chemical, Mannheim, Germany). During each cycle on the
real time of reaction and after completion of primer extension
at 72℃, fluorescence at 530 nm (F1 channel) was recorded.
The amount of IL-12R 2 mRNA was calculated relative to
the amount of GAPDH present in each sample and described
as IL-12R 2/GAPDH ratio. All the analysis was performed
in duplicate. Melting curve analysis was used to detect non-
specific amplification which could be occurred during PCR
procedures using SYBR green I (Fig. 1). 
Fragment of exon 13 including nucleotide 2451 of IL-
12R 2 was amplified from mRNA and genomic DNA, re-
spectively. The PCR thermal conditions were as follows: 5
min at 94℃and 40 cycles of 20 sec at 94℃, 20 sec at 65℃
and 45 sec at 72℃ for mRNA and 10 min at 94℃ and 40
cycles of 1 min at 94℃, 1 min at 55℃ and 1 min at 72℃
Uses Target Primer sequences
Quantitative IL-12R 2 S5 ′ -ACATTCTTGGACATAGTG-
real time PCR AGGCC-3′
AS 5′ -GTACATCTGCTCACGGAA-
GCC-3′
GAPDH S 5′ -CGTCTTCACCACCATGGA-
GA-3′
AS 5′ -CGGCCATCACGCCACAG-
TTT-3′
Sequencing IL-12R 2 S5 ′ -GATGACAGCTCTGACAG-
analysis cDNA CTG-3′
AS 5′ -GGCCTGATGACCTTGGA-
IT-3′
IL-12R 2 S5 ′ -GATGACAGCTCTGACAGC-
genomic DNA TG-3′
AS 5′ -CATTGTCTCCAGGAAGA-
TAG-3′
Table 1. Primers for quantitative real time PCR and sequencing
analysis 
S, sense; AS, antisense.
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Fig. 1. Melting curves of amplification products of IL-12R 2 mRNA (A) and GAPDH (B). Solid arrow indicates non-specific primer-dimers
product. 
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for genomic DNA. The primer sequences were summarized
in Table 1. The amplified products were purified and sequ-
enced in automatic sequencer ABI prism
� 3730xI (Applied
Bisosystems, Foster City, CA, U.S.A.). 
Serum total IgE concentration was measured using RIDA
AllergyScreen test kit (R-biopharm AG, Darmstadt, Ger-
many). Peripheral blood eosinophil count was measured using
ADVIA120 (Bayer, Dublin, Ireland). 
Statistical analysis 
The comparison of IL-12R 2 mRNA expression between
atopic patients including 3 disease groups and healthy con-
trols was analyzed using independent t test. The compari-
son of IL-12R 2 mRNA expression among 3 disease groups
was analyzed using one way ANOVA. The relationship bet-
ween IL-12R 2 mRNA expression and serum total IgE were
analyzed using one way ANOVA. The relationship between
IL-12R 2 mRNA expression and blood eosinophil count was
analyzed using Spearman’s correlation test. All the statistical
analysis was performed with SPSS program (version 12.0,
SPSS Inc, Chicago, IL, U.S.A.) and the p value of <0.05 was
considered as significant. 
RESULTS
The PHA stimulated PBMCs from atopic patients had sig-
nificantly lower expression of IL-12R 2mRNA than the cells
from healthy controls (p<0.05) (Fig. 2). The average IL-12R 2/
GAPDH ratio was 0.035±0.02 in healthy controls and 0.018
±0.047 in atopic patients. When patients were divided into
3 disease groups (asthma, atopic dermatitis, allergic rhinitis),
each disease group showed lower IL-12R 2 mRNA expres-
sion than controls (p<0.05, respectively), also. But there was
no significant difference of IL-12R 2 mRNA expression
between 3 groups (p>0.05) (Table 2). 
In the results of sequencing analysis, all the nucleotide 2451
was cytidine (C) in cDNA as well as genomic DNA from
atopic patients and healthy controls (Fig. 3). Therefore, the
RNA editing phenomenon, C-to-U conversion at nucleotide
2451 of IL-12R 2 was not found in present study. 
The atopic patients were divided into 3 groups according
to the semiquantitative results of serum total IgE (<100 IU/
mL, 100-200 mIU/mL and >200 IU/mL) and the average
IL-12R 2/GAPDH ratio was 0.008±0.007, 0.008±0.007
and 0.028±0.064, respectively. When the expression of IL-
12R 2 mRNA was compared, there was no significant dif-
ferences among groups (p>0.05) (Fig. 4). The correlation
between IL-12R 2 mRNA expression and blood eosinophil
count was not found, either (p<0.05) (Fig. 5). 
A
C TCTGACA GCTGCTGGTGAA
Nucleotide 2451
AGTTCCC A
B
CT CTGA CA GCTGCT GGTGAA
Nucleotide 2451
AGTTCCCA
Fig. 3. Results of sequencing analysis of IL-12R 2 cDNA (A) and genomic DNA (B). Both bases of nucleotide 2451 of cDNA and genomic
DNA are cytosines in atopic patients and healthy controls. Arrows indicate the base composition of nucleotide 2451 on exon 13. 
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Fig. 2. Comparison of IL-12R 2/GAPDH ratio between healthy con-
trols (n=54) and atopic patients (n=80). The mRNA expression of
IL-12R 2 is significantly lower in atopic patients than healthy con-
trols (p<0.05). 
IL-12R 2/GAPDH ratio
Atopic patients (n=80) 0.0177±0.0465*
Asthma (n=14) 0.0102±0.0072
�
Allergic rhinitis (n=42) 0.0232±0.063
�
Atopic dermatitis (n=26) 0.0128±0.0191
�
Healthy controls (n=54) 0.0345±0.0193
Table 2. Results of IL-12R 2 mRNA expression manifested by
IL-12R 2/GAPDH ratio
*p<0.05 by independent t test compared with healthy controls. 
� p >0.05
by one way ANOVA compared among asthma, allergic rhinitis and atopic
dermatitis. Values are mean±SD.mRNA Expression and RNA Editing of IL-12R 2 in Atopy 1073
DISCUSSION
IL-12 is the single most powerful factor to induce Th1 im-
mune response. It is produced by antigen present cells (APCs),
including monocytes and dendritic cells. IL-12 is a heterodi-
meric cytokine composed of 35 and 40 kDa peptides and the
genes are located on chromosome 3 and 5, respectively (11).
By binding to its specific receptor complex,  1 and  2, IL-
12 promotes the development of Th1 responses and induces
production of IFN- . The  2 subunit is the signal transduc-
ing component of the receptor and highly regulated in con-
trast to the  1 subunit. IFN- inhibits Th cells to differen-
tiate to Th2 cells and down-regulates the production of IgE
in B lymphocytes. IFN- is also able to augment IL-12. This
IL-12/IFN- loop helps the predominant Th1 cell differen-
tiation and inhibits Th2 cell differentiation (12). 
Since it was reported that PBMCs from atopic patients pro-
duced less IFN- than those of healthy individuals when they
were stimulated with IL-12 (5-9), several investigations to
find genetic mechanisms from interaction between IL-12 and
IL-12R have been reported. Several IL-12 polymorphism or
IL-12R 2 mutations such as truncated (2496 del 91) or mis-
sense (1577 A to G and 2799 A to G) mutation has been re-
ported (13). Although these mutations were thought to lead
to change in the conformational structure of  2 receptor, these
are controversial, yet. In a recent study, the relationship bet-
ween RNA editing of IL-12R 2 and atopy was reported by
Kondo et al. (1). RNA editing is defined when there is any
specific alteration in primary sequence of a RNA molecule.
Such changes have marked effects on gene expression. They
found that the patients who had nucleotide 2451 C-to-U
conversion showed lower IFN- production and faint tyro-
sine phosphorylation of STAT-4 than those who did not have
editing. This C-to-U conversion cause substitution of amino
acid alanine to valine. Therefore, they proposed that the RNA
editing might cause impairment of the IL-12 signal cascade
and the subsequent reduction in IFN- production by dis-
turbing conformational binding of IL-12 to IL-12R. Unfor-
tunately, we could not find the C-to-U conversion at nucleo-
tide 2451 from either atopic patients or healthy controls. 
In other studies, the expression of IL-12R 2 mRNA was
studied in atopy (10, 14). PBMCs from children with atopic
airway symptoms showed lower mRNA expression of IL-
12R 2than non-atopic children and the production of IFN-
after stimulation with IL-12 was also lower in atopic children.
In present study, we also found that PBMCs from atopic pa-
tients expressed lower IL-12R 2mRNA than those of healthy
controls. This low expression findings of IL-12R 2 mRNA
was found in all 3 atopic disease groups, but significant dif-
ferences was not found between groups. These results corre-
spond with previous studies and support their hypothesis that
reduced capacity of up-regulation of IL-12R 2 may contribute
to the Th2-skewed immune response in atopic patients.
The underlying mechanism of low mRNA expression of
IL-12R 2 in atopic patients cannot be known yet. But there
was a suggestion to introduce association of CD2 defects and
low responsiveness to IL-12. In previous and present studies,
the PBMCs were stimulated with phytohaemagglutinin,
which activates lymphocytes via CD2. CD2 is an accessory
molecule of T cell and has been thought to synergize the IL-
12 action by up-regulation of the  2 chain (15, 16). Besides,
the lower proportion of CD2+ lymphocytes was detected
in atopic children (17). But further studies will be required
whether there is connection between CD2 and atopy.
In additional evaluation, we also analyzed the relationship
between IL-12R 2 mRNA expression and serum total IgE
concentration or eosinophil count. There were not any sig-
nificant associations between them. This result indicates that
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Fig. 4. Comparison of IL-12R 2/GAPDH ratio among 3 groups di-
vided by serum total IgE concentration. Significant difference is
not found between 3 groups (one way ANOVA, p>0.05). 
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Fig. 5. Relationship between IL-12R 2/GAPDH ratio and blood
eosinophil count in atopic patients. Significant relationship between
IL-12R 2 mRNA expression and blood eosinophil count is not
found (Spearman’s correlation test, p>0.05). 1074 E.J. Kim, W.M. Lee, J.S. Ha, et al.
the IL-12R 2 mRNA expression would not affect produc-
tion of IgE or eosinophils, directly. However, we thought that
this analysis would be more reliable if we analyzed serum IgE
concentration with quantitative method. In one study, a neg-
ative correlation between IL-2-induced IL-12R 2 mRNA
expression and serum IgE concentration had been reported
(10). 
In conclusion, RNA editing which might cause the confor-
mational changes in IL-12R 2 was not found, but less IL-
12R 2 mRNA on response to PHA stimulation was found
in atopic patients. This low expression of IL-12R 2 did not
have relationship with atopic disease category, serum IgE
concentration or blood eosinophil count. We guess low expres-
sion of IL-12R 2 may contribute to low responsiveness to
IL-12, low production of IFN- and Th2-skewed immuni-
ty in atopic patients, subsequently. 
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